Reports Q4 revenue $6.84B, consensus $6.81B. Rainer Blair, president and CEO, stated, “We delivered a strong finish to the year with better-than-expected performance across our portfolio. We were particularly encouraged by continued strength in our bioprocessing business, along with improved momentum in Diagnostics and Life Sciences. Our teams’ disciplined execution also enabled us to exceed our fourth quarter margin, earnings, and cash flow expectations.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- These Are the Stocks Reporting Earnings Today – January 28, 2026
- Notable companies reporting before tomorrow’s open
- DHR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- The Week That Was, The Week Ahead: Macro and Markets, Jan. 25
- Positioned for Long-Duration Growth: Danaher’s Emerging Leadership in Blood-Based Alzheimer’s Diagnostics